Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Lanabecestat (Primary) ; Rosuvastatin
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 19 Jun 2017 Status changed from active, no longer recruiting to completed.
- 03 May 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2017 Planned End Date changed from 9 Apr 2017 to 22 May 2017.